» Articles » PMID: 38469587

Identifying Patients at Risk for Myasthenic Crisis with Hemogram and Inflammation-related Laboratory Parameters - a Pilot Study

Abstract

Background: Myasthenia gravis (MG) is a rare autoimmune disease characterized by fatigable weakness of the voluntary muscles and can exacerbate to life-threatening myasthenic crisis (MC), requiring intensive care treatment. Routine laboratory parameters are a cost-effective and widely available method for estimating the clinical outcomes of several diseases, but so far, such parameters have not been established to detect disease progression in MG.

Methods: We conducted a retrospective analysis of selected laboratory parameters related to inflammation and hemogram for MG patients with MC compared to MG patients without MC. To identify potential risk factors for MC, we applied time-varying Cox regression for time to MC and, as a sensitivity analysis, generalized estimating equations logistic regression for the occurrence of MC at the next patient visit.

Results: 15 of the 58 examined MG patients suffered at least one MC. There was no notable difference in the occurrence of MC by antibody status or sex. Both regression models showed that higher counts of basophils (per 0.01 unit increase: HR = 1.32, 95% CI = 1.02-1.70), neutrophils (per 1 unit increase: HR = 1.40, 95% CI = 1.14-1.72), potentially leukocytes (per 1 unit increase: HR = 1.15, 95% CI = 0.99-1.34), and platelets (per 100 units increase: HR = 1.54, 95% CI = 0.99-2.38) may indicate increased risk for a myasthenic crisis.

Conclusion: This pilot study provides proof of the concept that increased counts of basophils, neutrophils, leukocytes, and platelets may be associated with a higher risk of developing MC in patients with MG.

Citing Articles

Identifying patients at risk for myasthenic crisis with hemogram and inflammation-related laboratory parameters - a pilot study.

Mehnert A, Bershan S, Kollmus-Heege J, Gerischer L, Herdick M, Hoffmann S Front Neurol. 2024; 15:1297997.

PMID: 38469587 PMC: 10925644. DOI: 10.3389/fneur.2024.1297997.

References
1.
Mergenthaler P, Stetefeld H, Dohmen C, Kohler S, Schonenberger S, Bosel J . Seronegative myasthenic crisis: a multicenter analysis. J Neurol. 2022; 269(7):3904-3911. PMC: 8988104. DOI: 10.1007/s00415-022-11023-z. View

2.
Meriggioli M, Sanders D . Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity. Lancet Neurol. 2009; 8(5):475-90. PMC: 2730933. DOI: 10.1016/S1474-4422(09)70063-8. View

3.
Neumann B, Angstwurm K, Mergenthaler P, Kohler S, Schonenberger S, Bosel J . Myasthenic crisis demanding mechanical ventilation: A multicenter analysis of 250 cases. Neurology. 2019; 94(3):e299-e313. DOI: 10.1212/WNL.0000000000008688. View

4.
Punga A, Maddison P, Heckmann J, Guptill J, Evoli A . Epidemiology, diagnostics, and biomarkers of autoimmune neuromuscular junction disorders. Lancet Neurol. 2022; 21(2):176-188. DOI: 10.1016/S1474-4422(21)00297-0. View

5.
Gamez J, Salvado M, Carmona F, de Nadal M, Romero L, Ruiz D . Intravenous immunoglobulin to prevent myasthenic crisis after thymectomy and other procedures can be omitted in patients with well-controlled myasthenia gravis. Ther Adv Neurol Disord. 2019; 12:1756286419864497. PMC: 6640060. DOI: 10.1177/1756286419864497. View